Formulations of a somatostatin modulator
AssigneeCrinetics Pharmaceuticals, Inc.
InventorsGerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler
Life of this patent
Estimating the term…
Abstract
Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Claims15
A method of suppressing growth hormone (GH), insulin, glucagon, insulin-like growth factor 1 (IGF-1), prolactin, or combinations thereof, in a human comprising orally administering to a human on an empty stomach at least 30 minutes before a meal a pharmaceutical composition comprising a therapeutically effective amount of 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutical acceptable ingredients.
Dependencies are inferred from the claim text.